Loading...
Leadership 2017-07-24T01:04:28+00:00

Management Team

Dr. Xu has served on Cesca’s board of directors since March 2016, and was appointed chairman and interim chief executive officer in November 2016. He brings to Cesca over 15 years of leadership experience in the biopharmaceutical industry and has contributed to numerous successful product launches. In 2009, Dr. Xu founded Boyalife Group, a China-based diversified life sciences holding company and is currently the principal shareholder of Cesca. Prior to founding Boyalife, Dr. Xu served as a project leader at Pfizer, as a director of research at two publicly-traded companies and as a vice president at Founder Group, a Chinese technology conglomerate focused on information technology, pharmaceuticals, real estate, finance, and commodities trading. Dr. Xu’s expertise spans several diverse therapeutic areas, including arthritis & inflammation, cardiovascular disease, autoimmunity, oncology and diabetes. He has authored over forty publications and has been recognized by numerous professional societies for his contributions to biomedical research. Dr. Xu received his Ph.D. in immunology from Washington University School of Medicine (St. Louis, USA) and an executive MBA from Emory University (Atlanta, USA).
Ms. Liu has served on Cesca’s board of directors since November 2016 and was appointed chief operating officer in February 2017. She has over 20 years of experience in finance, operations and M&A at both public and private biopharmaceutical companies. Prior to joining Cesca, Ms. Liu served as managing director at OxOnc Services Company, an oncology product development company. From 1994 to 2010, she served in various executive roles at NexMed, Inc., later renamed Apricus Biosciences Inc., which she co-founded. Ms. Liu obtained her MPA in international finance from the University of Southern California and her B.A. from the University of California, Berkley.
Mr. Coelho joined Cesca as chief technology officer from SynGen Inc. in July 2017, where he was CTO and co-founder. Mr. Coelho is an engineer and inventor who has been awarded more than 30 U.S. patents related to cell cryopreservation, cryogenic robotics, cell selection, blood protein harvesting, and surgical hemostasis.

Prior to cofounding SynGen, Mr. Coelho founded and ran several companies, including  Cesca’s device division, Thermogenesis Corp., where he also served as chairman and chief executive officer. At ThermoGenesis, he led the development of many of the company’s key products, including the Thermoline ultra rapid blood plasma freezers and thawers, the CryoSeal automated system for preparing fibrin sealant from a surgical patient’s blood, the BioArchive robotic system for controlled-rate freezing and cryogenically archiving units of hematopoietic stem and progenitor cells (HSPCs) derived from placental/cord blood and the AutoXpress System, which automates the sterile harvesting of HSPCs from cord blood into a 25 ml dual-compartment freezing bag. The BioArchive® and AutoXpress® Systems have defined cGMP standards in cord blood processing and banking worldwide.

In 2002, Mr. Coelho initiated an effort to obtain federal funding sufficient to allow qualified public cord blood banks to build a substantial inventory of ethnically diverse, clinical grade, cord blood stem cell units for all patients in need. Passed unanimously by Congress and signed by President Bush on December 19, 2005, the “Stem Cell Therapeutic and Research Act of 2005” authorized and began financing of a national inventory of 150,000 units of cryopreserved, HLA typed, cord blood stem cells and a website that allowed transplant physicians to choose optimal stem cell units for the treatment of blood cancers such as leukemia, myeloma, and lymphoma; inherited immunodeficiencies and marrow failure disorders and inherited disorders or errors of metabolism. During this last decade, Mr. Coelho has gathered detailed knowledge of the practices of the major public and private cord blood banks in 30 countries and has developed working relationships with many scientists, clinicians and directors associated with these cord blood banks.

As CTO of Cesca, Mr. Coehlo is leading the development of new products for the clinical and research fields that improve the speed and efficiency of harvesting target cell populations resident within peripheral or placental/cord blood or bone marrow and washing/purifying ex-vivo expanded cell populations derived from those cells.

Mr. Coelho holds a Bachelor’s degree in mechanical engineering from the University of California, Davis.

Ms. Zhu currently serves as general manager for the Company’s Thermogenesis device division. Since joining in 2004, Ms. Zhu has contributed significantly to the establishment of Thermogenesis’ commercial presence in China. Ms. Zhu has over 20 years of technical and sales experience in stem cell research. She started her career as a research scientist at Harvard Medical School Stem Cell Lab and BioTransplant, Inc. Ms. Zhu graduated from the Shanghai University of Science & Technology with a degree in biology and also studied statistics at Boston University.
Mr. Hoseit joined Cesca in July 2017 from SynGen Inc., where he also served as senior vice president of research and development. He has been developing and commercializing electronic instrumentation and imaging products for multiple industries for nearly 30 years, including over 15 years of medical device product development experience at Evena Medical, Volcano Corporation, and others. During his career, Mr. Hoseit has led the development and release of several intra-vascular imaging and measurement medical devices, several of which went on to become major platforms with multiple diagnostic modes. While at Volcano, he was responsible for over 80 technical personnel in the medical device engineering department, consisting of various disciplines (software, hardware, signal and image processing, program management, systems and sustaining) and with an annual budget of over $13 million.

Mr. Hoseit has designed many electronic instruments (analog and digital) and personally developed embedded and digital signal processing software for real time diagnostic equipment. He has developed product development processes, defined product roadmaps, led quality system implementation teams and holds nine patents. He earned a B.S. in biology from Santa Clara University, as well as a B.S. in electrical engineering and an M.S. in biomedical engineering, both from California State University at Sacramento.

Mr. Hodl joined Cesca in July 2017 from SynGen Inc., and brings 19 years of experience in product commercialization and business development in the life science and medical products industries. He has served as president of SynGen’s Cell Processing Business Unit since 2014 and, before that, as business development manager at Becton Dickinson Technologies (BD), BD’s Corporate Innovation Center. At BD, he led the commercialization of several cell-based technologies, including BD FACS CAP™, an antibody-based cell surface marker profiling platform, as well as BD’s Discovery Platform, a custom cell culture environment development service. He also played a leading role in executing the development partnership between BD and Fate Therapeutics to access proprietary technology for developing products for expansion and differentiation of induced pluripotent stem cells. Mr. Hodl was also instrumental in assessing opportunities for BD to develop next generation sequencing technologies.

Prior to BD, David held leadership positions at several emerging companies focused on pharmacogenomics services and hepatic cell-based products and services, including Gentris Corporation and CellzDirect, among others. He earned a B.S. in biology from Linfield College and an MBA from North Carolina State University with a focus on technology commercialization.

Mr. Cauble, principal accounting officer, joined Cesca in 2010 and has served in various accounting management positions of increasing responsibility. Mr. Cauble has over 19 years of accounting experience in various financial and managerial roles for companies such as Diamond Foods Inc. and E.&J. Gallo Winery. Mr. Cauble obtained a B.S. in accounting and finance from the University of Idaho and is a certified public accountant.
Ms. Ellner joined Cesca in 2003 and has held various positions of increasing responsibility, including senior director of global supply chain and senior director of operations, before being named to her current position in March 2016. She has more than 25 years of operations experience in the medical device industry. Prior to joining Cesca, Ms. Ellner held senior positions at Oratech Interventions, Inc. (now Smith and Nephew) and Stryker Corporation. Ms. Ellner obtained a BS in manufacturing administration with honors from Western Michigan University.
Dr. Ponemone joined Cesca’s India division, TotipotentRX, in 2008 and currently serves as executive director and director of clinical development operations. He also oversees operations at the state-of-the-art cGMP cell processing facility for hematopoietic stem cell transplantation and cord blood banking at the Fortis-TotipotentRX Centre for Cellular Medicine, Fortis Memorial Research Institute, Gurgaon, India. Prior to joining TotipotentRX, Dr. Ponemone was an assistant professor of medical microbiology at Kamineni Graduate School of Medicine, Hyderabad, India. He has authored more than 45 peer-reviewed publications on regenerative medicine, the role of cytokines in autoimmune disease, and radioprotective and chemoprotective agents in cancer treatment. Dr. Ponemone is a Fellow of Academic General Education at Manipal University, where he earned his Ph.D. in radiation biology and oncology, his post-graduate degree in medical microbiology and his MBA.